Please login to the form below

Not currently logged in
Email:
Password:

John Brown joins board of BioCity Nottingham

Appointment follows expansion of BioCity's operations to Scotland

Dr John Brown, current chair of CXR Biosciences, has been appointed to the board of directors at BioCity Nottingham – one of Europe's largest life sciences research parks.

Dr Brown is also currently non-executive director of Vectura Group, chair of the Roslin Foundation in Scotland and co-chair of the Life Sciences Industry Advisory Board for the Scottish Government.

Other public sector work includes serving as non-executive director of the UK's Technology Strategy Board, a national agency to support innovation in business.

His appointment comes shortly after BioCity Nottingham announced plans to extend its operations, with the launch of BioCity Scotland in January, 2012, using a research facility formerly owned by Merck Sharp & Dohme.

Commenting on his appointment, Dr Brown said: “I'm delighted to be working with the BioCity team. Emulating the successful BioCity model at BioCity Scotland is just the first step for a company with exceptional growth potential.''

Previous positions held by Dr Brown in an extensive career in the life sciences industry include chair of both BTG and Axis-Shield, as well as spending five years at Glaxo Group Research.

He was also chief executive of UK-based vaccines biotech Acambis from 1997 until 2003.

Dr Louis Nisbet, chair of BioCity said: “Few individuals have the depth and breadth of experience that [Dr Brown] will bring to BioCity and to the companies we support.”

14th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics